LCB01 0371

Drug Profile

LCB01 0371

Alternative Names: LCB-01371

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LegoChem Biosciences
  • Class Antibacterials; Oxazolidinones
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gram-positive infections

Most Recent Events

  • 12 Dec 2016 Phase-II clinical trials in Gram-positive infections in South Korea (PO) before December 2016 (NCT02836483)
  • 12 Dec 2016 LCB01 0371 licensed to RMX Biopharma in China
  • 01 Sep 2016 Phase-I clinical trials in Gram-positive infections (In volunteers) in South Korea (IV) (NCT02882789)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top